Log in
NASDAQ:CCXI

ChemoCentryx Competitors

$52.04
-1.40 (-2.62 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$51.89
Now: $52.04
$54.19
50-Day Range
$46.35
MA: $53.53
$59.28
52-Week Range
$7.50
Now: $52.04
$65.43
Volume387,614 shs
Average Volume652,817 shs
Market Capitalization$3.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7

Competitors

ChemoCentryx (NASDAQ:CCXI) Vs. AMGN, CELG, GILD, REGN, VRTX, and BIIB

Should you be buying CCXI stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to ChemoCentryx, including Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), and Biogen (BIIB).

Amgen (NASDAQ:AMGN) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Amgen and ChemoCentryx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.74$7.84 billion$14.8215.45
ChemoCentryx$36.13 million99.23$-55,490,000.00($0.98)-53.10

Amgen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 76.4% of ChemoCentryx shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 9.3% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Amgen and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen30.04%91.98%15.24%
ChemoCentryx-39.19%-19.57%-10.27%

Analyst Recommendations

This is a breakdown of recent recommendations for Amgen and ChemoCentryx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1131402.46
ChemoCentryx00813.11

Amgen presently has a consensus price target of $255.68, suggesting a potential upside of 11.67%. ChemoCentryx has a consensus price target of $72.4444, suggesting a potential upside of 39.21%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts plainly believe ChemoCentryx is more favorable than Amgen.

Volatility & Risk

Amgen has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Summary

Amgen beats ChemoCentryx on 8 of the 15 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Celgene and ChemoCentryx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celgene04002.00
ChemoCentryx00813.11

Celgene presently has a consensus price target of $108.6667, suggesting a potential upside of 0.39%. ChemoCentryx has a consensus price target of $72.4444, suggesting a potential upside of 39.21%. Given ChemoCentryx's stronger consensus rating and higher probable upside, analysts clearly believe ChemoCentryx is more favorable than Celgene.

Earnings & Valuation

This table compares Celgene and ChemoCentryx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celgene$15.28 billion5.04$4.05 billion$7.6114.22
ChemoCentryx$36.13 million99.23$-55,490,000.00($0.98)-53.10

Celgene has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celgene and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celgene34.63%78.15%18.54%
ChemoCentryx-39.19%-19.57%-10.27%

Insider & Institutional Ownership

71.7% of Celgene shares are owned by institutional investors. Comparatively, 76.4% of ChemoCentryx shares are owned by institutional investors. 0.4% of Celgene shares are owned by company insiders. Comparatively, 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Celgene has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Summary

ChemoCentryx beats Celgene on 8 of the 15 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ChemoCentryx and Gilead Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx00813.11
Gilead Sciences2151002.30

ChemoCentryx presently has a consensus price target of $72.4444, suggesting a potential upside of 39.21%. Gilead Sciences has a consensus price target of $78.9259, suggesting a potential upside of 31.08%. Given ChemoCentryx's stronger consensus rating and higher possible upside, equities research analysts plainly believe ChemoCentryx is more favorable than Gilead Sciences.

Profitability

This table compares ChemoCentryx and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-39.19%-19.57%-10.27%
Gilead Sciences-1.16%33.59%11.89%

Risk and Volatility

ChemoCentryx has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Valuation & Earnings

This table compares ChemoCentryx and Gilead Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million99.23$-55,490,000.00($0.98)-53.10
Gilead Sciences$22.45 billion3.36$5.39 billion$6.149.81

Gilead Sciences has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.4% of ChemoCentryx shares are owned by institutional investors. Comparatively, 77.9% of Gilead Sciences shares are owned by institutional investors. 9.3% of ChemoCentryx shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Gilead Sciences beats ChemoCentryx on 8 of the 15 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Risk & Volatility

ChemoCentryx has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Insider & Institutional Ownership

76.4% of ChemoCentryx shares are held by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares ChemoCentryx and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-39.19%-19.57%-10.27%
Regeneron Pharmaceuticals37.30%26.71%19.39%

Valuation & Earnings

This table compares ChemoCentryx and Regeneron Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million99.23$-55,490,000.00($0.98)-53.10
Regeneron Pharmaceuticals$7.86 billion7.74$2.12 billion$21.4726.66

Regeneron Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx00813.11
Regeneron Pharmaceuticals091412.67

ChemoCentryx presently has a consensus price target of $72.4444, indicating a potential upside of 39.21%. Regeneron Pharmaceuticals has a consensus price target of $622.1250, indicating a potential upside of 8.69%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts clearly believe ChemoCentryx is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats ChemoCentryx on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and ChemoCentryx (NASDAQ:CCXI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vertex Pharmaceuticals and ChemoCentryx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082012.76
ChemoCentryx00813.11

Vertex Pharmaceuticals presently has a consensus price target of $294.00, indicating a potential upside of 39.09%. ChemoCentryx has a consensus price target of $72.4444, indicating a potential upside of 39.21%. Given ChemoCentryx's stronger consensus rating and higher possible upside, analysts clearly believe ChemoCentryx is more favorable than Vertex Pharmaceuticals.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and ChemoCentryx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.23$1.18 billion$4.2949.27
ChemoCentryx$36.13 million99.23$-55,490,000.00($0.98)-53.10

Vertex Pharmaceuticals has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.4% of ChemoCentryx shares are owned by institutional investors. 0.5% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and ChemoCentryx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
ChemoCentryx-39.19%-19.57%-10.27%

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats ChemoCentryx on 9 of the 14 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Earnings and Valuation

This table compares ChemoCentryx and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million99.23$-55,490,000.00($0.98)-53.10
Biogen$14.38 billion2.96$5.89 billion$33.578.01

Biogen has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChemoCentryx and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-39.19%-19.57%-10.27%
Biogen40.91%50.10%24.10%

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx00813.11
Biogen4161102.23

ChemoCentryx currently has a consensus target price of $72.4444, suggesting a potential upside of 39.21%. Biogen has a consensus target price of $311.8214, suggesting a potential upside of 15.96%. Given ChemoCentryx's stronger consensus rating and higher probable upside, equities research analysts clearly believe ChemoCentryx is more favorable than Biogen.

Insider and Institutional Ownership

76.4% of ChemoCentryx shares are held by institutional investors. Comparatively, 83.7% of Biogen shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

ChemoCentryx has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Summary

Biogen beats ChemoCentryx on 9 of the 15 factors compared between the two stocks.


ChemoCentryx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$228.97-0.9%$134.11 billion$23.36 billion18.71Upcoming Earnings
Dividend Announcement
Celgene logo
CELG
Celgene
1.7$108.24-0.0%$77.04 billion$15.28 billion14.22
Gilead Sciences logo
GILD
Gilead Sciences
2.7$60.21-0.6%$75.49 billion$22.45 billion-250.86Upcoming Earnings
Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$572.40-0.7%$60.90 billion$7.86 billion22.16
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$211.38-1.5%$56.80 billion$4.16 billion26.69Upcoming Earnings
Analyst Report
Biogen logo
BIIB
Biogen
1.7$268.91-0.7%$42.57 billion$14.38 billion7.88Earnings Announcement
Analyst Report
Analyst Revision
Heavy News Reporting
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$197.71-0.2%$34.40 billion$916.71 million-130.93Upcoming Earnings
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.6$118.19-4.9%$25.90 billion$4.99 billion31.60Upcoming Earnings
Analyst Revision
Immunomedics logo
IMMU
Immunomedics
1.2$87.82-0.1%$20.30 billion$290,000.00-50.76
Incyte logo
INCY
Incyte
1.6$88.60-0.8%$19.38 billion$2.16 billion-97.36
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$136.48-3.6%$15.83 billion$219.75 million-18.03Upcoming Earnings
Analyst Downgrade
Analyst Revision
Exact Sciences logo
EXAS
Exact Sciences
1.2$99.61-3.4%$14.96 billion$876.29 million-93.97Upcoming Earnings
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.7$77.50-0.5%$14.05 billion$1.70 billion117.42Upcoming Earnings
Heavy News Reporting
Repligen logo
RGEN
Repligen
1.2$171.76-0.4%$9.02 billion$270.24 million296.14Upcoming Earnings
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.2$95.82-3.3%$8.94 billion$788.10 million45.41Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$21.79-2.2%$6.73 billion$967.78 million24.48
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$46.36-2.2%$6.48 billion$1.12 billion52.68
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
0.9$52.48-0.0%$6.25 billion$23.87 million-24.75Upcoming Earnings
Novavax logo
NVAX
Novavax
1.9$91.16-7.9%$5.59 billion$18.66 million-33.15Analyst Downgrade
United Therapeutics logo
UTHR
United Therapeutics
1.5$118.85-0.3%$5.11 billion$1.45 billion12.20High Trading Volume
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.1$93.04-3.9%$4.92 billion$1.11 billion28.98
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$17.64-3.7%$4.57 billion$182.24 million-15.47Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.4$76.01-2.3%$4.38 billion$806.43 million-11.13Analyst Downgrade
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.4$30.06-0.5%$4.12 billion$195.99 million-115.62Insider Selling
Unusual Options Activity
Analyst Revision
Heavy News Reporting
Opko Health logo
OPK
Opko Health
2.4$4.18-6.7%$2.80 billion$901.90 million-12.65Upcoming Earnings
Analyst Revision
Alkermes logo
ALKS
Alkermes
1.7$16.26-4.1%$2.59 billion$1.17 billion-20.32Upcoming Earnings
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.6$127.09-0.6%$1.96 billionN/A-14.59Decrease in Short Interest
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.37-2.2%$1.46 billion$102.43 million-12.49
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.05-5.2%$1.45 billion$428.41 million14.84Upcoming Earnings
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.8$80.55-10.1%$1.30 billion$120.28 million-58.37Analyst Downgrade
High Trading Volume
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$14.02-4.9%$1.05 billion$638.60 million-5.23
Innoviva logo
INVA
Innoviva
0.9$9.74-1.6%$987.56 million$261.02 million4.73Heavy News Reporting
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$29.48-3.1%$972.28 million$252 million-2.85Increase in Short Interest
ImmunoGen logo
IMGN
ImmunoGen
1.6$5.23-0.4%$912.86 million$82.27 million-12.16Analyst Report
Codexis logo
CDXS
Codexis
1.5$13.93-0.9%$823.64 million$68.46 million-58.04
Agenus logo
AGEN
Agenus
1.5$4.04-2.5%$741.11 million$150.05 million-3.54Upcoming Earnings
Unusual Options Activity
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.6$16.69-2.5%$653.01 million$3.57 million-6.37Analyst Report
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.30-0.6%$648.56 million$38.19 million35.60Analyst Downgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.1$3.59-2.2%$633.87 million$48.83 million-4.27
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$10.02-2.7%$589.68 million$227.19 million4.79Heavy News Reporting
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.4$2.26-7.5%$580.35 million$150,000.00-3.23
Geron logo
GERN
Geron
2.0$1.83-1.1%$568.16 million$460,000.00-4.95Analyst Downgrade
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.48-8.9%$507.15 million$109.33 million-2.85
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.49-4.2%$484.23 million$143.01 million-0.90
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.58-6.6%$478.22 million$22.27 million-3.68Analyst Downgrade
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.9$13.63-0.1%$470.28 million$327.75 million-1.77
MannKind logo
MNKD
MannKind
1.9$2.02-0.5%$462.93 million$63.04 million-9.62Analyst Upgrade
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.5$4.17-0.7%$456.67 million$35.22 million-2.44
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$2.47-4.0%$417.26 million$59.29 million-17.64
PDL BioPharma logo
PDLI
PDL BioPharma
2.0$2.21-0.0%$251.90 million$54.76 million-1.66
This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.